Your browser doesn't support javascript.
loading
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.
Abedin, Sameem; Rashid, Nahid; Schroeder, Mark; Romee, Rizwan; Nauffal, Mary; Alhaj Moustafa, Muhamad; Kharfan-Dabaja, Mohamed A; Palmer, Jeanne; Hogan, William; Hefazi, Mehrdad; Larson, Samantha; Holtan, Shernan; DeFilipp, Zachariah; Jayani, Reena; Dholaria, Bhagirathbhai; Pidala, Joseph; Khimani, Farhad; Grunwald, Michael R; Butler, Candace; Hamadani, Mehdi.
Afiliação
  • Abedin S; Blood & Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Rashid N; Division of Hematology, University of Washington, Seattle, WA, USA.
  • Schroeder M; Division of Oncology, Washington University, St Louis, MO, USA.
  • Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Nauffal M; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alhaj Moustafa M; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
  • Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
  • Palmer J; Division of Hematology/Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.
  • Hogan W; Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
  • Hefazi M; Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
  • Larson S; Hematology/Oncology Pharmacy Program, M Health Fairview, Maple Grove, MN, USA.
  • Holtan S; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA.
  • DeFilipp Z; Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA, USA.
  • Jayani R; Division of Hematology and Oncology, Vanderbilt University, Nashville, TN, USA.
  • Dholaria B; Division of Hematology and Oncology, Vanderbilt University, Nashville, TN, USA.
  • Pidala J; Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Khimani F; Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Butler C; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Hamadani M; Blood & Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Br J Haematol ; 195(3): 429-432, 2021 11.
Article em En | MEDLINE | ID: mdl-34254289
ABSTRACT
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Doença Enxerto-Hospedeiro / Nitrilas Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Doença Enxerto-Hospedeiro / Nitrilas Idioma: En Ano de publicação: 2021 Tipo de documento: Article